Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Expected to Post Earnings of -$0.75 Per Share

Equities research analysts forecast that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) will report earnings per share (EPS) of ($0.75) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Checkmate Pharmaceuticals’ earnings. Checkmate Pharmaceuticals posted earnings per share of ($0.88) during the same quarter last year, which suggests a positive year over year growth rate of 14.8%. The company is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Checkmate Pharmaceuticals will report full-year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($3.05). For the next financial year, analysts forecast that the company will report earnings of ($2.83) per share, with EPS estimates ranging from ($4.11) to ($1.55). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Checkmate Pharmaceuticals.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last released its quarterly earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter.

A number of analysts have recently weighed in on CMPI shares. Zacks Investment Research upgraded shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 3rd. BTIG Research downgraded shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 20th.

Checkmate Pharmaceuticals stock opened at $10.47 on Friday. The stock has a market cap of $230.76 million, a P/E ratio of -3.59 and a beta of -4.84. Checkmate Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $10.48. The firm’s fifty day moving average price is $6.40 and its 200-day moving average price is $4.28.

In related news, major shareholder Global Strategic Fund I. Venbio sold 95,800 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $10.45, for a total transaction of $1,001,110.00. Following the sale, the insider now directly owns 2,155,930 shares of the company’s stock, valued at $22,529,468.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Global Strategic Fund I. Venbio sold 62,200 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $10.38, for a total transaction of $645,636.00. Following the transaction, the insider now directly owns 3,125,640 shares in the company, valued at $32,444,143.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,015,021 shares of company stock worth $10,544,455. 62.60% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CMPI. Millennium Management LLC purchased a new position in shares of Checkmate Pharmaceuticals in the fourth quarter valued at approximately $31,000. BlackRock Inc. lifted its position in shares of Checkmate Pharmaceuticals by 126.7% during the 3rd quarter. BlackRock Inc. now owns 51,794 shares of the company’s stock worth $205,000 after buying an additional 28,944 shares during the last quarter. Finally, Decheng Capital Management III Cayman LLC purchased a new stake in shares of Checkmate Pharmaceuticals during the 1st quarter worth approximately $4,253,000. 74.56% of the stock is owned by institutional investors and hedge funds.

Checkmate Pharmaceuticals Company Profile (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Featured Stories

Get a free copy of the Zacks research report on Checkmate Pharmaceuticals (CMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Checkmate Pharmaceuticals (NASDAQ:CMPI)

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.